NGM438 (Not yet branded)
Other Medications
Description
NGM438 is a novel therapeutic compound currently in early-phase clinical development for advanced or metastatic solid tumors, including colorectal cancer. This agent is being evaluated both as a single agent and in combination with the PD-1 inhibitor pembrolizumab for patients with treatment-refractory malignancies. NGM438 represents part of NGM Biopharmaceuticals' pipeline targeting specific molecular pathways in cancer progression.
Mechanism of Action
The precise molecular mechanism of action for NGM438 has not been fully disclosed in public documentation. Based on NGM Biopharmaceuticals' focus on growth factor and metabolic pathway modulation, NGM438 likely targets key signaling cascades involved in tumor growth, metastasis, or the tumor microenvironment.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.